David E Briles

Birmingham, AL, United States of America

David E Briles

USPTO Granted Patents = 29 

 

 

Average Co-Inventor Count = 2.6

ph-index = 10

Forward Citations = 275(Granted Patents)


Company Filing History:


Years Active: 1995-2023

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents

Title: David E. Briles: Innovator in Pneumococcal Vaccine Research

Introduction

David E. Briles, based in Birmingham, AL, is a prolific inventor known for his significant contributions to the field of immunology and vaccine development. With an impressive portfolio of 29 patents, his work primarily focuses on innovative solutions for preventing pneumococcal infections.

Latest Patents

Briles' latest patents include groundbreaking advancements in pneumococcal vaccines. One major patent details a pneumococcal vaccine that combines selected alpha helical domains and proline-rich domains of pneumococcal surface protein A. This invention lays out methods for creating novel recombinant protein immunogens designed to enhance immunogenic responses against a wide variety of pneumococcal serotypes. Another significant patent presents compositions aimed at reducing bacterial carriage and central nervous system invasion, highlighting the use of pneumococcal neuraminidase, phosphocholine, and antigenic components. These advancements underscore Briles' commitment to combating pneumococcal disease through innovative vaccine strategies.

Career Highlights

Throughout his distinguished career, Briles has played a crucial role at notable research institutions. His contributions at the University of Alabama at Birmingham Research Foundation have been vital in advancing the understanding of pneumococcal diseases and the development of effective vaccines. His expertise has not only been recognized through patents but also through collaborations with esteemed professionals in the field.

Collaborations

Briles has collaborated with several notable figures during his career, including Janet L. Yother and Susan K. Hollingshead. These partnerships have fostered a productive environment for innovation and research, enabling the translation of ideas into tangible solutions in vaccine development.

Conclusion

David E. Briles stands out as a leading innovator in the realm of pneumococcal vaccine development. His array of patents reflects a deep commitment to enhancing public health through scientific research and innovation. The impact of his work is likely to be felt for years to come, as his inventions pave the way for new approaches to prevent and treat pneumococcal infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…